Randomized Controlled Trial of Pulpotomy in Primary Molars using MTA and Formocresol Compared to 3Mixtatin: A Novel Biomaterial

Objective: This study was conducted to compare the efficacy of 3Mixtatin (a combination of simvastatin and 3Mix antibiotic) with MTA and Formocresol for the pulpotomy of primary molars. Study design: 114 children aged 3–6 years old with 150 primary molars were randomly allocated to three groups. MTA, Formocresol or 3Mixtatin were used for Pulpotomies. Hard setting zinc oxide eugenol was used to cover these materials. The teeth were restored with amalgam. Blinded radiographic and clinical examinations were conducted at 6, 12 and 24 months after treatment for the presence of pain, tenderness to palpation and percussion, sinus tract, swelling, presence of internal or external root resorption, inter-radicular radiolucency, and periapical lesion. Results: 122 teeth were available for 24-month follow-up study. The overall success rate was 78.9% for FC, 90.5% for 3Mixtatin and 88.1% for MTA group. There was no significant difference in overall success rate among the groups after 24-month follow-up (X²=2.43, df = 2, P =0.27). Conclusion: Our findings demonstrated remarkable results of 3Mixtatin in pulpotomy of primary teeth at the 24-month follow-up. Therefore, 3Mixtatin may be considered as an effective material in pulpotomy of primary teeth because of its successful results.

Pulpotomy, Primary teeth, mineral trioxide aggregate

1. Moretti AB, Sakai VT, Oliveira TM et al. The effectiveness of mineral trioxide aggregate, calcium hydroxide and formocresol for pulpotomies in primary teeth. Int Endod J. 41: 547-555, 2008.

2. Fuks AB. Vital pulp therapy with new materials for primary teeth: new directions and Treatment perspectives. Pediatr Dent. 30: 211-219, 2008.

3. Havale R, Anegundi RT, Indushekar K, Sudha P. Clinical and radiographic evaluation of pulpotomies in primary molars with formocresol, glutaralde-hyde and ferric sulphate. Oral Health Dent Manag. 12: 24-31, 2013.

4. Ratnakumari N, Thomas B. A Histopathological Comparison of Pulpal Response to Chitra-CPC and Formocresol used as Pulpotomy Agents in Primary Teeth: A Clinical Trial. International Journal of Clinical Pediatric Dentistry. 5: 6-13, 2012.

5. Samiei M, Ghasemi N, Asl-Aminabadi N, Divband B, Golparvar-Dashti Y, Shirazi S. Zeolite-silver-zinc nanoparticles: Biocompatibility and their effect on the compressive strength of mineral trioxide aggregate. J Clin Exp Dent. 9: e356-e360, 2017.

6. Chandrashekhar S, Shashidhar J. Formocresol, still a controversial material for pulpotomy: A critical literature review. Journal of Restorative Dentistry. 2: 114-124, 2014.

7. Aminabadi NA, Farahani RMZ, Gajan EB. A clinical study of formocresol pulpotomy versus root canal therapy of vital primary incisors. J Clin Pediatr Dent. 32: 211-214, 2008.

8. Cuadros-Fernandez C, Lorente Rodriguez AI, Saez-Martinez S, Garcia-Binimelis J, About I, Mercade M. Short-term treatment outcome of pulpotomies in primary molars using mineral trioxide aggregate and Biodentine: a randomized clinical trial. Clin Oral Investig. 2015.

9. Kusum B, Rakesh K, Richa K. Clinical and radiographical evaluation of mineral trioxide aggregate, biodentine and propolis as pulpotomy medica-ments in primary teeth. Restor Dent Endod. 40: 276-285, 2015.

10. Shayegan A, Petein M, Abbeele AV. Beta-tricalcium phosphate, white mineral trioxide aggregate, white Portland cement, ferric sulfate, and formocresol used as pulpotomy agents in primary pig teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 105: 536-542, 2008.

11. Torabinejad M, Chivian N. Clinical applications of mineral trioxide aggre-gate. J Endod. 25: 197-205, 1999.

12. Holan G, Eidelman E, Fuks AB. Long-term evaluation of pulpotomy in primary molars using mineral trioxide aggregate or formocresol. Pediatr Dent. 27: 129-136, 2005.

13. Parirokh M, Torabinejad M. Mineral trioxide aggregate: a comprehensive literature review—Part III: Clinical applications, drawbacks, and mecha-nism of action. J Endod. 36: 400-413, 2010.

14. Asl Aminabadi N, Satrab S, Najafpour E, Samiei M, Jamali Z, Shirazi S. A randomized trial of direct pulp capping in primary molars using MTA compared to 3Mixtatin: a novel pulp capping biomaterial. Int J Paediatr Dent. 26: 281-290, 2016.

15. Samiei M, Janani M, Asl-Aminabadi N et al. Effect of the TiO2 nanoparti-cles on the selected physical properties of mineral trioxide aggregate. J Clin Exp Dent. 9: e191-e195, 2017.

16. Aminabadi NA, Huang B, Samiei M, Agheli S, Jamali Z, Shirazi S. A Randomized Trial Using 3Mixtatin Compared to MTA in Primary Molars with Inflammatory Root Resorption: A Novel Endodontic Biomaterial. J Clin Pediatr Dent. 40: 95-102, 2016.

17. Aminabadi NA, Najafpour E, Erfanparast L et al. Oral health status, dental anxiety, and behavior-management problems in children with oppositional defiant disorder. Eur J Oral Sci. 124: 45-51, 2016.

18. Aminabadi NA, Najafpour E, Aghaee S, Sighari Deljavan A, Jamali Z, Shirazi S. Use of general anaesthesia in paediatric dentistry: barriers to discriminate between true and false cases. Eur Arch Paediatr Dent. 17: 89- 95, 2016.

19. AAPD. Guideline on pulp therapy for primary and Immature permanent teeth. Pediatr Dent. 37: 244-252, 2015-2016.

20. Aaminabadi NA, Parto M, Emamverdizadeh P, Jamali Z, Shirazi S. Pulp bleeding color is an indicator of clinical and histohematologic status of primary teeth. Clin Oral Investig. 21(5):1831-1841.

21. Jamali Z, Aminabadi NA, Samiei M, Sighari Deljavan A, Shokravi M, Shirazi S. Impact of Chlorhexidine Pretreatment Followed by Probiotic Streptococcus salivarius Strain K12 on Halitosis in Children: A Randomised Controlled Clinical Trial. Oral Health Prev Dent. 14: 305-313, 2016.

22. Silveira CM, Sanchez-Ayala A, Lagravere MO, Pilatti GL, Gomes OM. Repair of furcal perforation with mineral trioxide aggregate: long-term follow-up of 2 cases. J Can Dent Assoc. 74: 729-733, 2008.

23. Nair PN, Duncan HF, Pitt Ford TR, Luder HU. Histological, ultrastructural and quantitative investigations on the response of healthy human pulps to experimental capping with mineral trioxide aggregate: a randomized controlled trial. Int Endod J. 41: 128-150, 2008.

24. Ayukawa Y, Yasukawa E, Moriyama Y et al. Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 107: 336-342, 2009.

25. Kamada A, Ikeo T, Tamura I et al. Statin promotes mineralization potential in MC3T3-E1 nonmineralizing subclone. Journal of Oral Tissue Engi-neering. 3: 169-174, 2006.

26. Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int. 69: 299-304, 2001.

27. Yoshinari M, Hayakawa T, Matsuzaka K et al. Oxygen plasma surface modification enhances immobilization of simvastatin acid. Biomed Res. 27: 29-36, 2006.

28. Samiei M, Aghazadeh M, Alizadeh E et al. Osteogenic/Odontogenic Bioengineering with co-Administration of Simvastatin and Hydroxyapatite on Poly Caprolactone Based Nanofibrous Scaffold. Adv Pharm Bull. 6: 353- 365, 2016.

29. Parirokh M, Torabinejad M. Mineral trioxide aggregate: a comprehensive literature review—Part I: chemical, physical, and antibacterial properties. J Endod. 36: 16-27, 2010.

30. Okamoto Y, Sonoyama W, Ono M et al. Simvastatin induces the odonto-genic differentiation of human dental pulp stem cells in vitro and in vivo. J Endod. 35: 367-372, 2009.

31. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvas-tatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 85: 520- 523, 2006.

32. Grover HS, Kapoor S, Singh A. Effect of topical simvastatin (1.2 mg) on gingival crevicular fluid interleukin-6, interleukin-8 and interleukin-10 levels in chronic periodontitis–A clinicobiochemical study. J Oral Biol Craniofac Res. 6: 85-92, 2016.

33. Nie P, Li D, Hu L et al. Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors. PLoS One. 9: e97009, 2014.

34. Hoshino E, Ando N, Sato M, Kota K. Bacterial invasion of non-exposed dental pulp. Int Endod J. 25: 2-5, 1992.

35. Takushige T, Hoshino E, Ando H. Endodontic retreatment using 3Mix-MP without removal of previous root canal obturation. J LSTR Ther (Interna-tional Web Version). 8: 3-7, 2009.

36. Jung IY, Lee SJ, Hargreaves KM. Biologically based treatment of immature permanent teeth with pulpal necrosis: a case series. J Endod. 34: 876-887, 2008.

37. Ng FK, Messer LB. Mineral trioxide aggregate as a pulpotomy medica-ment: an evidence-based assessment. Eur Arch Paediatr Dent. 9: 58-73, 2008.

38. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol. 161: 218-228, 1994.

39. Olatosi OO, Sote EO, Orenuga OO. Effect of mineral trioxide aggregate and formocresol pulpotomy on vital primary teeth: a clinical and radio-graphic study. Niger J Clin Pract. 18: 292-296, 2015.

40. Godhi B, Sood PB, Sharma A. Effects of mineral trioxide aggregate and formocresol on vital pulp after pulpotomy of primary molars: An in vivo study. Contemporary Clinical Dentistry. 2: 296-301, 2011.

41. Alqaderi H, Lee CT, Borzangy S, Pagonis TC. Coronal pulpotomy for cari-ously exposed permanent posterior teeth with closed apices: A systematic review and meta-analysis. J Dent. 44: 1-7, 2016.

42. Eskandarinezhad M, Shahveghar-Asl N, Sharghi R et al. Sealing efficacy of mineral trioxide aggregate with and without nanosilver for root end filling: An in vitro bacterial leakage study. J Clin Exp Dent. 9: e27-e33, 2017.